Enhancing heart failure treatment decisions: interpretable machine learning models for advanced therapy eligibility
Yufeng Zhang1, Jessica R Golbus2, Emily Wittrup3
1Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, 48103, MI, USA. chloezh@umich.edu.
BMC Medical Informatics and Decision Making
|February 14, 2024
Summary
New models predict heart failure patients needing advanced therapies using electronic health records. These models improve patient outcomes and identify key risk factors for better heart failure management.
Area of Science:
- Cardiology
- Biomedical Informatics
- Machine Learning
Background:
- Timely referral for advanced heart failure therapies is crucial for patient outcomes.
- Current decision-making is complex, time-consuming, and requires specialized expertise.
- Electronic Health Records (EHRs) contain valuable sequential data for prediction.
Purpose of the Study:
- To develop and evaluate logistic tensor regression (LTR) models for predicting heart failure patients requiring advanced therapies.
- To analyze model performance at both population and individual levels using EHR data.
- To identify key clinical features and comorbidities associated with advanced therapy referral.
Main Methods:
- Proposed two LTR models (standard and personalized) utilizing irregularly spaced sequential EHR data.
- Collected clinical features from previous visits for predictions at the start of subsequent visits.
- Conducted patient-wise ten-fold cross-validation and compared with other machine learning models.
Main Results:
- Standard LTR achieved an average F1 score of 0.708, AUC of 0.903, and AUPRC of 0.836.
- Personalized LTR achieved an F1 score of 0.670, AUC of 0.869, and AUPRC of 0.839.
- The LTR models outperformed other machine learning methods and improved their performance through weight transfer.
Conclusions:
- The proposed LTR models effectively predict the need for advanced heart failure therapies using EHR data.
- Identified significant clinical features like chronic kidney disease and hypotension, validated by experts.
- The models offer insights into risk factors for heart failure progression at population and individual levels.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure Drugs: β-Blockers
340
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
340


